FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
James M ClearyNora K HorickNadine Jackson McClearyThomas A AbramsMatthew B YurgelunChristopher G AzzoliDouglas A RubinsonGabriel A BrooksJennifer A ChanLawrence S BlaszkowskyJeffrey W ClarkLipika GoyalJeffrey A MeyerhardtKimmie NgDeborah SchragDiane M F SavareseChristopher GrahamBridget FitzpatrickKathryn A GibbYves BoucherDan G DudaRakesh K JainCharles S FuchsPeter C EnzingerPublished in: Cancer (2019)
Ziv-aflibercept did not increase the anti-tumor activity of first-line mFOLFOX6 in metastatic esophagogastric cancer, potentially because of decreased dose intensity of FOLFOX. Further evaluation of ziv-aflibercept in unselected, chemotherapy-naive patients with metastatic esophagogastric adenocarcinoma is not warranted.
Keyphrases
- squamous cell carcinoma
- double blind
- locally advanced
- metastatic colorectal cancer
- age related macular degeneration
- placebo controlled
- small cell lung cancer
- phase ii study
- phase iii
- papillary thyroid
- open label
- clinical trial
- rectal cancer
- squamous cell
- hiv infected
- high intensity
- radiation therapy
- antiretroviral therapy